Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNT-ORPHAN-05
- Development stage
- Preclinical
- Lead developer
- Centurion
- Modality
- Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
CNT-ORPHAN-05 is a small molecule systemic anti-infective drug candidate being developed by Centurion (Centurion Pharma) for the treatment of rare or orphan diseases. Formulated as a vial for parenteral administration, the agent is part of Centurion's specialized R&D pipeline focused on addressing unmet medical needs in the field of infectious diseases. While the specific biological target and mechanism of action have not been publicly disclosed, the drug is positioned within the company's portfolio of orphan products, which aims to provide therapeutic options for conditions with limited treatment availability in the Turkish and international markets.
Beyond the preview
Go deeper on CNT-ORPHAN-05.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNT-ORPHAN-05.